drugset / Trial / NCT00067743
A Study of CC-5013 in the Treatment of Complex Regional Pain Syndrome (CRPS)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a multicenter, open-label study in adult subjects with Type 1 Complex Regional Pain Syndrome. Subjects diagnosed with unilateral Type 1 CRPS will be enrolled sequentially to receive CC-5013 10 mg/day orally. For each subject the study consists of two phases: Pre-treatment phase(1 wk) and treatment phase (12 wks)
Timeline
- Start
- 2003-08
- Primary completion
- 2004-10
- Completion
- 2007-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | 10 mg | Oral |